Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap ($3.57 Billion)
Market Cap & Net Worth: Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Amneal Pharmaceuticals, Inc. Class A Common Stock market cap. Amneal Pharmaceuticals, Inc. Class A Common Stock (NYSE:AMRX) has a market capitalization of $3.57 Billion ($3.57 Billion) as of November 8, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #4281 globally and #1496 in its home market, demonstrating a -2.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amneal Pharmaceuticals, Inc. Class A Common Stock's stock price $12.18 by its total outstanding shares 314362920 (314.36 Million). Also see cash efficiency ratio of Amneal Pharmaceuticals, Inc. Class A Com for how efficiently the company converts equity into cash flow.
Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap History (2015–2025)
Amneal Pharmaceuticals, Inc. Class A Common Stock market cap history from 2015 to 2025. Data shows change from $13.44 Billion to $3.83 Billion (-10.58% CAGR). Check AMRX share price today for real-time trading data and today's change.
Index Memberships
Amneal Pharmaceuticals, Inc. Class A Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.14% | #113 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.01% | #493 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.20% | #72 of 263 |
Weight: Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amneal Pharmaceuticals, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Amneal Pharmaceuticals, Inc. Class A Com (AMRX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.89x
Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $13.44 Billion | $866.28 Million | $169.45 Million | 15.52x | 79.33x |
| 2016 | $4.17 Billion | $1.02 Billion | $207.38 Million | 4.09x | 20.09x |
| 2017 | $5.23 Billion | $1.03 Billion | $167.65 Million | 5.06x | 31.22x |
| 2018 | $4.25 Billion | $1.66 Billion | -$169.73 Million | 2.56x | N/A |
| 2019 | $1.52 Billion | $1.63 Billion | -$603.57 Million | 0.93x | N/A |
| 2020 | $1.44 Billion | $1.99 Billion | $91.06 Million | 0.72x | 15.78x |
| 2021 | $1.51 Billion | $2.09 Billion | $10.62 Million | 0.72x | 141.74x |
| 2022 | $625.58 Million | $2.21 Billion | -$129.99 Million | 0.28x | N/A |
| 2023 | $1.91 Billion | $2.39 Billion | -$83.99 Million | 0.80x | N/A |
| 2024 | $2.49 Billion | $2.79 Billion | -$116.89 Million | 0.89x | N/A |
Competitor Companies of AMRX by Market Capitalization
Companies near Amneal Pharmaceuticals, Inc. Class A Common Stock in the global market cap rankings as of November 8, 2026. Also see AMRX current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Amneal Pharmaceuticals, Inc. Class A Common Stock by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
Market capitalization of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to today. Between 2015 and today, Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap moved from $13.44 Billion to $ 3.83 Billion, with a yearly change of -10.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.83 Billion | +53.79% |
| 2024 | $2.49 Billion | +30.48% |
| 2023 | $1.91 Billion | +205.03% |
| 2022 | $625.58 Million | -58.46% |
| 2021 | $1.51 Billion | +4.81% |
| 2020 | $1.44 Billion | -5.19% |
| 2019 | $1.52 Billion | -64.38% |
| 2018 | $4.25 Billion | -18.74% |
| 2017 | $5.23 Billion | +25.66% |
| 2016 | $4.17 Billion | -69.01% |
| 2015 | $13.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Amneal Pharmaceuticals, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.57 Billion USD |
| MoneyControl | $3.57 Billion USD |
| MarketWatch | $3.57 Billion USD |
| marketcap.company | $3.57 Billion USD |
| Reuters | $3.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate an… Read more